董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jay S. Duker | 男 | Chair of the Board | 62 | 10.58万美元 | 未持股 | 2021-03-15 |
| Carrie L. Bourdow | 女 | Director | 58 | 12.63万美元 | 未持股 | 2021-03-15 |
| Jason A. Keyes | 男 | Director | 49 | 12.76万美元 | 未持股 | 2021-03-15 |
| Thomas R. Cannell | 男 | President and Chief Executive Officer and Director | 59 | 170.25万美元 | 未持股 | 2021-03-15 |
| Jane V. Henderson | 女 | Director | 55 | 8.71万美元 | 未持股 | 2021-03-15 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas R. Cannell | 男 | President and Chief Executive Officer and Director | 59 | 170.25万美元 | 未持股 | 2021-03-15 |
| Monica Forbes | 女 | Chief Financial Officer and Treasurer | 45 | 79.53万美元 | 未持股 | 2021-03-15 |
| Glen MacDonald | 男 | Chief Technology Officer | 63 | 67.47万美元 | 未持股 | 2021-03-15 |
| Mark R. Sullivan | 男 | General Counsel & Corporate Secretary | 49 | 93.77万美元 | 未持股 | 2021-03-15 |
董事简历
中英对照 | 中文 | 英文- Jay S. Duker
-
Jay S. Duker自2015年1月以来一直担任我们董事会的成员。他曾一直担任 the New England Eye Center NEEC 的多种职务（1992年1月以来），最近担任董事（2001年以来）。他也曾担任Tufts Medical Center 、the Tufts University School of Medicine的教授和美国眼科部门主席（2003年以来）。他发表了超过185篇文章。他的主要研究兴趣包括视网膜成像（特别是光学相干断层扫描（OCT））、视网膜血管疾病和后段药物输送。他的著作《Yanoff and Duker’s Ophthalmology》是过去10年最畅销的眼科文本。他是3家公司（包括Hemera Biosciences公司，一个生物技术新创公司，专注于治疗年龄相关性黄斑变性的基因疗法）的创始人之一。他持有Harvard University的学士学位，以及the Jefferson Medical College at Thomas Jefferson University的医学博士学位。
Jay S. Duker has served as a member of our Board since January 2015 and Chairman of the Board since February 2020. Dr. Duker has served in varying capacities at the New England Eye Center NEEC since January 1992 most recently as Director since 2001. Dr. Duker has served as the Chief Strategic Scientific Officer of EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) since July 2020. Dr. Duker is Professor and Chairman of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine. He has published more than 350 journal articles, with his major research interests including retinal imaging, in particular optical coherence tomography (OCT), retinal vascular diseases, and drug delivery to the posterior segment. His book, Yanoff and Duker’s Ophthalmology, is one of the bestselling ophthalmic texts over the past decade. Dr. Duker is the co-founder of three companies, including Hemera Biosciences, a clinical stage biotech company whose focus is a gene therapy based treatment for age-related macular degeneration. Dr. Duker served on the board of directors of EyePoint Pharmaceuticals, Inc. from September 2016 to December 2020. Dr. Duker received an A.B. from Harvard University and a M.D. from the Jefferson Medical College at Thomas Jefferson University. - Jay S. Duker自2015年1月以来一直担任我们董事会的成员。他曾一直担任 the New England Eye Center NEEC 的多种职务（1992年1月以来），最近担任董事（2001年以来）。他也曾担任Tufts Medical Center 、the Tufts University School of Medicine的教授和美国眼科部门主席（2003年以来）。他发表了超过185篇文章。他的主要研究兴趣包括视网膜成像（特别是光学相干断层扫描（OCT））、视网膜血管疾病和后段药物输送。他的著作《Yanoff and Duker’s Ophthalmology》是过去10年最畅销的眼科文本。他是3家公司（包括Hemera Biosciences公司，一个生物技术新创公司，专注于治疗年龄相关性黄斑变性的基因疗法）的创始人之一。他持有Harvard University的学士学位，以及the Jefferson Medical College at Thomas Jefferson University的医学博士学位。
- Jay S. Duker has served as a member of our Board since January 2015 and Chairman of the Board since February 2020. Dr. Duker has served in varying capacities at the New England Eye Center NEEC since January 1992 most recently as Director since 2001. Dr. Duker has served as the Chief Strategic Scientific Officer of EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) since July 2020. Dr. Duker is Professor and Chairman of the Department of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine. He has published more than 350 journal articles, with his major research interests including retinal imaging, in particular optical coherence tomography (OCT), retinal vascular diseases, and drug delivery to the posterior segment. His book, Yanoff and Duker’s Ophthalmology, is one of the bestselling ophthalmic texts over the past decade. Dr. Duker is the co-founder of three companies, including Hemera Biosciences, a clinical stage biotech company whose focus is a gene therapy based treatment for age-related macular degeneration. Dr. Duker served on the board of directors of EyePoint Pharmaceuticals, Inc. from September 2016 to December 2020. Dr. Duker received an A.B. from Harvard University and a M.D. from the Jefferson Medical College at Thomas Jefferson University.
- Carrie L. Bourdow
-
Carrie L. Bourdow自2015年5月起担任公司高级副总裁兼首席商务官。2013年5月至2015年5月，她在Cubist Pharmaceuticals, Inc.担任营销副总裁。2013年加入Cubist之前，Bourdow女士在Merck & Co., Inc.任职20多年，在那里她在多个治疗领域担任越来越重要的职务，包括抗感染、急性心脏衰竭和疼痛。 Bourdow女士获得了Hendrix College的学士学位和 Southern Illinois University的工商管理硕士学位。
Carrie L. Bourdow has served as a member of our Board since February 2020. Ms. Bourdow has served as the President, Chief Executive Officer and a member of the board of directors of Trevena, Inc. Nasdaq: TRVN since October 2018. Prior to her role as Chief Executive Officer, Ms. Bourdow joined Trevena as Senior Vice President and Chief Commercial Officer in May 2015 and was appointed Executive Vice President and Chief Operating Officer in January 2018. Prior to joining Trevena, Ms. Bourdow was Vice President of Marketing at Cubist Pharmaceuticals, Inc., from May 2013 until its acquisition by Merck & Co., Inc. in May 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for products totaling over $1 billion in annual revenues. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across commercial functions and therapeutic areas. Since June 2017 she has served on the board of directors of Nabriva Therapeutics plc. (Nasdaq: NBRV), a publicly traded biopharmaceutical company. - Carrie L. Bourdow自2015年5月起担任公司高级副总裁兼首席商务官。2013年5月至2015年5月，她在Cubist Pharmaceuticals, Inc.担任营销副总裁。2013年加入Cubist之前，Bourdow女士在Merck & Co., Inc.任职20多年，在那里她在多个治疗领域担任越来越重要的职务，包括抗感染、急性心脏衰竭和疼痛。 Bourdow女士获得了Hendrix College的学士学位和 Southern Illinois University的工商管理硕士学位。
- Carrie L. Bourdow has served as a member of our Board since February 2020. Ms. Bourdow has served as the President, Chief Executive Officer and a member of the board of directors of Trevena, Inc. Nasdaq: TRVN since October 2018. Prior to her role as Chief Executive Officer, Ms. Bourdow joined Trevena as Senior Vice President and Chief Commercial Officer in May 2015 and was appointed Executive Vice President and Chief Operating Officer in January 2018. Prior to joining Trevena, Ms. Bourdow was Vice President of Marketing at Cubist Pharmaceuticals, Inc., from May 2013 until its acquisition by Merck & Co., Inc. in May 2015. At Cubist, Ms. Bourdow led launch strategy, marketing, reimbursement, and operations for products totaling over $1 billion in annual revenues. Prior to Cubist, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across commercial functions and therapeutic areas. Since June 2017 she has served on the board of directors of Nabriva Therapeutics plc. (Nasdaq: NBRV), a publicly traded biopharmaceutical company.
- Jason A. Keyes
-
JasonA.Keyes自2020年2月起担任董事会成员。凯斯先生曾担任Equillium，Inc.的首席财务官。纳斯达克股票代码:EQ自2018年3月以来。在加入Equillium之前，他于2016年6月至2018年2月担任OrexigenTherapeutics，Inc.执行Vice President兼首席财务官，在为产品组合的全球商业化制定业务和财务战略方面发挥了关键作用。在担任首席财务官之前，凯斯先生于2015年2月至2016年6月担任Orexigen财务Vice President。在此之前，2007年8月至2013年1月，凯斯先生在AmylinPharmaceuticals，Inc.公司（一家上市生物制药公司）担任越来越重要的职务。在其职业生涯早期，凯斯先生曾在Amgen，Inc.（一家上市生物制药公司）和Baxter梦百合Corporation（一家上市梦百合公司）担任财务和公司战略领导职务。在他的职业生涯中，Keyes先生一直负责领导整个生物技术价值链的财务规划，管理投资者关系，筹集资金并推动业务发展。
Jason A. Keyes has served as a member of our Board since February 2020. Mr. Keyes has served as the Chief Financial Officer of Equillium, Inc. Nasdaq: EQ since March 2018. Prior to joining Equillium, he was Executive Vice President and Chief Financial Officer of Orexigen Therapeutics, Inc. from June 2016 to February 2018 where he played a key role in setting the business and financial strategy for the global commercialization of the product portfolio. Prior to his role as Chief Financial Officer, Mr. Keyes, held the position of Vice President, Finance at Orexigen from February 2015 to June 2016. Orexigen filed a voluntary petition for Chapter 11 bankruptcy in March 2018. Before that, Mr. Keyes held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from August 2007 until January 2013. Earlier in his career, Mr. Keyes held leadership positions in finance and corporate strategy at Amgen, Inc., a publicly-held biopharmaceutical company, and Baxter Healthcare Corporation, a publicly-held healthcare company. Over his career, Mr. Keyes has been responsible for leading financial planning across the biotechnology value chain, managing investor relations, raising capital, and driving business development. - JasonA.Keyes自2020年2月起担任董事会成员。凯斯先生曾担任Equillium，Inc.的首席财务官。纳斯达克股票代码:EQ自2018年3月以来。在加入Equillium之前，他于2016年6月至2018年2月担任OrexigenTherapeutics，Inc.执行Vice President兼首席财务官，在为产品组合的全球商业化制定业务和财务战略方面发挥了关键作用。在担任首席财务官之前，凯斯先生于2015年2月至2016年6月担任Orexigen财务Vice President。在此之前，2007年8月至2013年1月，凯斯先生在AmylinPharmaceuticals，Inc.公司（一家上市生物制药公司）担任越来越重要的职务。在其职业生涯早期，凯斯先生曾在Amgen，Inc.（一家上市生物制药公司）和Baxter梦百合Corporation（一家上市梦百合公司）担任财务和公司战略领导职务。在他的职业生涯中，Keyes先生一直负责领导整个生物技术价值链的财务规划，管理投资者关系，筹集资金并推动业务发展。
- Jason A. Keyes has served as a member of our Board since February 2020. Mr. Keyes has served as the Chief Financial Officer of Equillium, Inc. Nasdaq: EQ since March 2018. Prior to joining Equillium, he was Executive Vice President and Chief Financial Officer of Orexigen Therapeutics, Inc. from June 2016 to February 2018 where he played a key role in setting the business and financial strategy for the global commercialization of the product portfolio. Prior to his role as Chief Financial Officer, Mr. Keyes, held the position of Vice President, Finance at Orexigen from February 2015 to June 2016. Orexigen filed a voluntary petition for Chapter 11 bankruptcy in March 2018. Before that, Mr. Keyes held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from August 2007 until January 2013. Earlier in his career, Mr. Keyes held leadership positions in finance and corporate strategy at Amgen, Inc., a publicly-held biopharmaceutical company, and Baxter Healthcare Corporation, a publicly-held healthcare company. Over his career, Mr. Keyes has been responsible for leading financial planning across the biotechnology value chain, managing investor relations, raising capital, and driving business development.
- Thomas R. Cannell
-
Thomas R.Cannell自2018年8月起担任我们的总裁兼首席执行官。在加入我们之前，Cannell博士于2016年7月至2018年7月担任OrexigenTherapeutics，Inc.首席运营官兼全球商业产品总裁，并于2015年3月至2016年6月担任首席商务官。在Orexigen时，Cannell博士领导了Contrave的成功商业化和盈利能力。在加入Orexigen之前，Cannell博士在默克制药公司公司工作了27年，他在该公司担任过全球商业化、消费者营销以及销售运营和管理方面的高级领导职务，负责开发阶段的项目和经批准的市场产品。任职Merck公司期间，他曾担任Merck Canada公司的总裁兼董事总经理（从2012年12月到2014年10月），以及MSD Japan公司（Merck&Co.的子公司）的首席营销官兼首席战略官，从2010年到2012年，他负责建立一个长期的战略流程和计划，管理数十亿美元的产品组合，并监管数千名员工。此外，他为默克（Merck&8217；S.）美国业务设计并成功试点了创新的，以客户为中心的商业模式。Cannell博士在华盛顿州立大学（Washington State University）获得DVM学位。
Thomas R. Cannell has served as our President and Chief Executive Officer since August 2018. Prior to joining us, Dr. Cannell served as Orexigen Therapeutics, Inc.’s Chief Operating Officer & President of Global Commercial Products from July 2016 to July 2018 and as its Chief Commercial Officer from March 2015 to June 2016. While at Orexigen, Dr. Cannell led the successful commercialization and profitability of Contrave®. Orexigen filed a voluntary petition for Chapter 11 bankruptcy in March 2018. Prior to Orexigen, Dr. Cannell spent 27 years with Merck & Co., Inc., where he held senior leadership positions in global commercialization, consumer marketing, and sales operations and management for both development-stage programs and approved marketed products. While with Merck, he served as President and Managing Director of Merck Canada from December 2012 to October 2014 and Chief Marketing Officer & Chief Strategy Officer for MSD Japan, a subsidiary of Merck & Co., from 2010 to 2012 where he was responsible for setting up a long-standing strategic process and plan, managed a multi-billion-dollar product portfolio and oversaw thousands of employees. In addition, he designed and successfully piloted an innovative, customer-centric commercial model for Merck’s U.S. business. Dr. Cannell received his DVM degree from Washington State University. - Thomas R.Cannell自2018年8月起担任我们的总裁兼首席执行官。在加入我们之前，Cannell博士于2016年7月至2018年7月担任OrexigenTherapeutics，Inc.首席运营官兼全球商业产品总裁，并于2015年3月至2016年6月担任首席商务官。在Orexigen时，Cannell博士领导了Contrave的成功商业化和盈利能力。在加入Orexigen之前，Cannell博士在默克制药公司公司工作了27年，他在该公司担任过全球商业化、消费者营销以及销售运营和管理方面的高级领导职务，负责开发阶段的项目和经批准的市场产品。任职Merck公司期间，他曾担任Merck Canada公司的总裁兼董事总经理（从2012年12月到2014年10月），以及MSD Japan公司（Merck&Co.的子公司）的首席营销官兼首席战略官，从2010年到2012年，他负责建立一个长期的战略流程和计划，管理数十亿美元的产品组合，并监管数千名员工。此外，他为默克（Merck&8217；S.）美国业务设计并成功试点了创新的，以客户为中心的商业模式。Cannell博士在华盛顿州立大学（Washington State University）获得DVM学位。
- Thomas R. Cannell has served as our President and Chief Executive Officer since August 2018. Prior to joining us, Dr. Cannell served as Orexigen Therapeutics, Inc.’s Chief Operating Officer & President of Global Commercial Products from July 2016 to July 2018 and as its Chief Commercial Officer from March 2015 to June 2016. While at Orexigen, Dr. Cannell led the successful commercialization and profitability of Contrave®. Orexigen filed a voluntary petition for Chapter 11 bankruptcy in March 2018. Prior to Orexigen, Dr. Cannell spent 27 years with Merck & Co., Inc., where he held senior leadership positions in global commercialization, consumer marketing, and sales operations and management for both development-stage programs and approved marketed products. While with Merck, he served as President and Managing Director of Merck Canada from December 2012 to October 2014 and Chief Marketing Officer & Chief Strategy Officer for MSD Japan, a subsidiary of Merck & Co., from 2010 to 2012 where he was responsible for setting up a long-standing strategic process and plan, managed a multi-billion-dollar product portfolio and oversaw thousands of employees. In addition, he designed and successfully piloted an innovative, customer-centric commercial model for Merck’s U.S. business. Dr. Cannell received his DVM degree from Washington State University.
- Jane V. Henderson
-
自2013年10月起，Jane V. Henderson担任公司董事会成员。自2013年2月起，她曾担任Kolltan Pharmaceuticals高级副总裁和首席商务官，这是一家生物制药公司。在加入KolltanPharmaceuticals前，从2010年6月至2012年6月，她担任ISTA Pharmaceuticals业务发展部副总裁，这是一家眼睛保健公司的，当时ISTA Pharmaceuticals 被Bausch + Lomb Incorporated收购。在加入ISTA Pharmaceuticals前，2009年9月至2010年6，她担任Axerion Pharmaceuticals业务发展部的执行副总裁，财务总监及业务发展主管，这是一家制药公司。2009年至2009年9月，提供独立的咨询服务。自2008年1月至2009年2月，她担任Panacos Pharmaceuticals执行副总裁，首席财务官兼首席商务官，这是一家制药公司。在此之前，她担任过HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers 和 Salomon Brothers多个高级投资银行里的职位。她获得了杜克大学的心理学学士学位。
Jane V. Henderson has served as a member of our Board since October 2013. Ms. Henderson has served as the Chief Financial Officer of Adagio Therapeutics since December 2020. Previously, Ms. Henderson served as the Chief Financial Officer of Turnstone Biologics from July 2018 to December 2020 and as the Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics, Inc., a biopharmaceutical company, from January 2017 to July 2018. Ms. Henderson served as the Senior Vice President, Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., a biopharmaceutical company, from February 2013 to November 2016 when Kolltan Pharmaceuticals was acquired by Celldex Therapeutics, Inc. Prior to joining Kolltan Pharmaceuticals, Ms. Henderson served as the Vice President, Business Development of ISTA Pharmaceuticals, Inc., an eye care company, from June 2010 to June 2012 when ISTA Pharmaceuticals was acquired by Bausch + Lomb Incorporated. Prior to joining ISTA Pharmaceuticals, Ms. Henderson served as the Executive Vice President, Chief Financial Officer and Head of Business Development of Axerion Pharmaceuticals, Inc., a pharmaceutical company, from September 2009 to June 2010 provided independent consulting services from February 2009 to September 2009 and served as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals, Inc., a pharmaceutical company, from January 2008 to February 2009. Prior to that, Ms. Henderson served in a variety of senior investment banking roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson currently serves on the board of directors of IVERIC bio, Inc. Nasdaq: ISEE, formerly Ophthotech Corporation, where she also serves as Chair of the Audit Committee, and on the board of directors of Akero Therapeutics, Inc. (Nasdaq: AKRO), where she serves as Chair of the Audit Committee and Chair of the Nominating and Corporate Governance Committee. Ms. Henderson received a B.S. in Psychology from Duke University. - 自2013年10月起，Jane V. Henderson担任公司董事会成员。自2013年2月起，她曾担任Kolltan Pharmaceuticals高级副总裁和首席商务官，这是一家生物制药公司。在加入KolltanPharmaceuticals前，从2010年6月至2012年6月，她担任ISTA Pharmaceuticals业务发展部副总裁，这是一家眼睛保健公司的，当时ISTA Pharmaceuticals 被Bausch + Lomb Incorporated收购。在加入ISTA Pharmaceuticals前，2009年9月至2010年6，她担任Axerion Pharmaceuticals业务发展部的执行副总裁，财务总监及业务发展主管，这是一家制药公司。2009年至2009年9月，提供独立的咨询服务。自2008年1月至2009年2月，她担任Panacos Pharmaceuticals执行副总裁，首席财务官兼首席商务官，这是一家制药公司。在此之前，她担任过HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers 和 Salomon Brothers多个高级投资银行里的职位。她获得了杜克大学的心理学学士学位。
- Jane V. Henderson has served as a member of our Board since October 2013. Ms. Henderson has served as the Chief Financial Officer of Adagio Therapeutics since December 2020. Previously, Ms. Henderson served as the Chief Financial Officer of Turnstone Biologics from July 2018 to December 2020 and as the Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics, Inc., a biopharmaceutical company, from January 2017 to July 2018. Ms. Henderson served as the Senior Vice President, Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., a biopharmaceutical company, from February 2013 to November 2016 when Kolltan Pharmaceuticals was acquired by Celldex Therapeutics, Inc. Prior to joining Kolltan Pharmaceuticals, Ms. Henderson served as the Vice President, Business Development of ISTA Pharmaceuticals, Inc., an eye care company, from June 2010 to June 2012 when ISTA Pharmaceuticals was acquired by Bausch + Lomb Incorporated. Prior to joining ISTA Pharmaceuticals, Ms. Henderson served as the Executive Vice President, Chief Financial Officer and Head of Business Development of Axerion Pharmaceuticals, Inc., a pharmaceutical company, from September 2009 to June 2010 provided independent consulting services from February 2009 to September 2009 and served as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals, Inc., a pharmaceutical company, from January 2008 to February 2009. Prior to that, Ms. Henderson served in a variety of senior investment banking roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson currently serves on the board of directors of IVERIC bio, Inc. Nasdaq: ISEE, formerly Ophthotech Corporation, where she also serves as Chair of the Audit Committee, and on the board of directors of Akero Therapeutics, Inc. (Nasdaq: AKRO), where she serves as Chair of the Audit Committee and Chair of the Nominating and Corporate Governance Committee. Ms. Henderson received a B.S. in Psychology from Duke University.
高管简历
中英对照 | 中文 | 英文- Thomas R. Cannell
Thomas R.Cannell自2018年8月起担任我们的总裁兼首席执行官。在加入我们之前，Cannell博士于2016年7月至2018年7月担任OrexigenTherapeutics，Inc.首席运营官兼全球商业产品总裁，并于2015年3月至2016年6月担任首席商务官。在Orexigen时，Cannell博士领导了Contrave的成功商业化和盈利能力。在加入Orexigen之前，Cannell博士在默克制药公司公司工作了27年，他在该公司担任过全球商业化、消费者营销以及销售运营和管理方面的高级领导职务，负责开发阶段的项目和经批准的市场产品。任职Merck公司期间，他曾担任Merck Canada公司的总裁兼董事总经理（从2012年12月到2014年10月），以及MSD Japan公司（Merck&Co.的子公司）的首席营销官兼首席战略官，从2010年到2012年，他负责建立一个长期的战略流程和计划，管理数十亿美元的产品组合，并监管数千名员工。此外，他为默克（Merck&8217；S.）美国业务设计并成功试点了创新的，以客户为中心的商业模式。Cannell博士在华盛顿州立大学（Washington State University）获得DVM学位。
Thomas R. Cannell has served as our President and Chief Executive Officer since August 2018. Prior to joining us, Dr. Cannell served as Orexigen Therapeutics, Inc.’s Chief Operating Officer & President of Global Commercial Products from July 2016 to July 2018 and as its Chief Commercial Officer from March 2015 to June 2016. While at Orexigen, Dr. Cannell led the successful commercialization and profitability of Contrave®. Orexigen filed a voluntary petition for Chapter 11 bankruptcy in March 2018. Prior to Orexigen, Dr. Cannell spent 27 years with Merck & Co., Inc., where he held senior leadership positions in global commercialization, consumer marketing, and sales operations and management for both development-stage programs and approved marketed products. While with Merck, he served as President and Managing Director of Merck Canada from December 2012 to October 2014 and Chief Marketing Officer & Chief Strategy Officer for MSD Japan, a subsidiary of Merck & Co., from 2010 to 2012 where he was responsible for setting up a long-standing strategic process and plan, managed a multi-billion-dollar product portfolio and oversaw thousands of employees. In addition, he designed and successfully piloted an innovative, customer-centric commercial model for Merck’s U.S. business. Dr. Cannell received his DVM degree from Washington State University.- Thomas R.Cannell自2018年8月起担任我们的总裁兼首席执行官。在加入我们之前，Cannell博士于2016年7月至2018年7月担任OrexigenTherapeutics，Inc.首席运营官兼全球商业产品总裁，并于2015年3月至2016年6月担任首席商务官。在Orexigen时，Cannell博士领导了Contrave的成功商业化和盈利能力。在加入Orexigen之前，Cannell博士在默克制药公司公司工作了27年，他在该公司担任过全球商业化、消费者营销以及销售运营和管理方面的高级领导职务，负责开发阶段的项目和经批准的市场产品。任职Merck公司期间，他曾担任Merck Canada公司的总裁兼董事总经理（从2012年12月到2014年10月），以及MSD Japan公司（Merck&Co.的子公司）的首席营销官兼首席战略官，从2010年到2012年，他负责建立一个长期的战略流程和计划，管理数十亿美元的产品组合，并监管数千名员工。此外，他为默克（Merck&8217；S.）美国业务设计并成功试点了创新的，以客户为中心的商业模式。Cannell博士在华盛顿州立大学（Washington State University）获得DVM学位。
- Thomas R. Cannell has served as our President and Chief Executive Officer since August 2018. Prior to joining us, Dr. Cannell served as Orexigen Therapeutics, Inc.’s Chief Operating Officer & President of Global Commercial Products from July 2016 to July 2018 and as its Chief Commercial Officer from March 2015 to June 2016. While at Orexigen, Dr. Cannell led the successful commercialization and profitability of Contrave®. Orexigen filed a voluntary petition for Chapter 11 bankruptcy in March 2018. Prior to Orexigen, Dr. Cannell spent 27 years with Merck & Co., Inc., where he held senior leadership positions in global commercialization, consumer marketing, and sales operations and management for both development-stage programs and approved marketed products. While with Merck, he served as President and Managing Director of Merck Canada from December 2012 to October 2014 and Chief Marketing Officer & Chief Strategy Officer for MSD Japan, a subsidiary of Merck & Co., from 2010 to 2012 where he was responsible for setting up a long-standing strategic process and plan, managed a multi-billion-dollar product portfolio and oversaw thousands of employees. In addition, he designed and successfully piloted an innovative, customer-centric commercial model for Merck’s U.S. business. Dr. Cannell received his DVM degree from Washington State University.
- Monica Forbes
Monica Forbes自2020年8月起担任我们的首席财务官。福布斯女士曾于2019年4月至2019年7月担任公司财务顾问，并于2019年8月1日加入公司担任财务Vice President。2018年7月至2019年4月，福布斯女士担任Nalpropion Pharmaceuticals，Inc.的Vice President兼首席财务官。在此之前，福布斯女士曾担任Orexigen Therapeutics的Vice President兼代理首席财务官，Inc.从2018年2月到Nalpropion&8217；于2018年7月收购Orexigen，从2016年10月至2018年2月担任Orexigen财务规划和分析FP&A高级总监，从2014年10月至2016年10月担任FP&A总监。Forbes女士拥有San Diego State University工商管理学士学位。
Monica Forbes has served as our Chief Financial Officer since August 2019. Ms. Forbes previously served as a finance consultant to the Company from April 2019 through July 2019 at which time she joined the Company as our Vice President, Finance since August 1 2019. From July 2018 to April 2019 Ms. Forbes served as the Vice President and Chief Financial Officer of Nalpropion Pharmaceuticals, Inc. Prior to that Ms. Forbes served as Vice President and acting Chief Financial Officer of Orexigen Therapeutics, Inc. from February 2018 until Nalpropion’s acquisition of Orexigen in July 2018 Senior Director of Financial Planning and Analysis FP&A of Orexigen from October 2016 to February 2018 and Director of FP&A from October 2014 to October 2016. Orexigen filed a voluntary petition for Chapter 11 bankruptcy in March 2018. Ms. Forbes holds a B.S. in Business Administration from San Diego State University.- Monica Forbes自2020年8月起担任我们的首席财务官。福布斯女士曾于2019年4月至2019年7月担任公司财务顾问，并于2019年8月1日加入公司担任财务Vice President。2018年7月至2019年4月，福布斯女士担任Nalpropion Pharmaceuticals，Inc.的Vice President兼首席财务官。在此之前，福布斯女士曾担任Orexigen Therapeutics的Vice President兼代理首席财务官，Inc.从2018年2月到Nalpropion&8217；于2018年7月收购Orexigen，从2016年10月至2018年2月担任Orexigen财务规划和分析FP&A高级总监，从2014年10月至2016年10月担任FP&A总监。Forbes女士拥有San Diego State University工商管理学士学位。
- Monica Forbes has served as our Chief Financial Officer since August 2019. Ms. Forbes previously served as a finance consultant to the Company from April 2019 through July 2019 at which time she joined the Company as our Vice President, Finance since August 1 2019. From July 2018 to April 2019 Ms. Forbes served as the Vice President and Chief Financial Officer of Nalpropion Pharmaceuticals, Inc. Prior to that Ms. Forbes served as Vice President and acting Chief Financial Officer of Orexigen Therapeutics, Inc. from February 2018 until Nalpropion’s acquisition of Orexigen in July 2018 Senior Director of Financial Planning and Analysis FP&A of Orexigen from October 2016 to February 2018 and Director of FP&A from October 2014 to October 2016. Orexigen filed a voluntary petition for Chapter 11 bankruptcy in March 2018. Ms. Forbes holds a B.S. in Business Administration from San Diego State University.
- Glen MacDonald
Glen MacDonald自2017年2月起担任我们的首席技术官。从2016年9月我们收购Viventia BioInc.到2017年2月，麦克唐纳博士担任我们的首席科学官。麦克唐纳博士于2012年至2016年9月担任Viventia BioInc.的首席科学官，并于2005年至2012年担任Viventia BioInc.的前身公司Viventia Biotech Inc.的首席科学官。在此之前，MacDonald从1997年到2005年担任Viventia Biotech Inc.多个研究相关职位。MacDonald博士从1996年到1997年持有马尼托巴癌症治疗研究基金会奖学金，同时从1995年到1997年担任马尼托巴大学癌症治疗研究基金会博士后。MacDonald博士还从1993年到1995年担任the University of North Carolina at Chapel Hill加拿大关节炎学会博士后研究员。他于1980年毕业于盖尔夫大学，获得遗传学学士学位，并获得理学硕士学位。以及1987年和1993年获得the University of Manitoba博士学位。
Glen MacDonald has served as our Chief Technology Officer since February 2017. From the time of our acquisition of Viventia Bio Inc. in September 2016 to February 2017 Dr. MacDonald served as our Chief Scientific Officer. Dr. MacDonald was Chief Scientific Officer of Viventia Bio Inc. from 2012 to September 2016 and of Viventia Bio Inc.'s predecessor company, Viventia Biotech Inc., from 2005 to 2012. Prior to that, Dr. MacDonald served Viventia Biotech Inc. in several research related capacities from 1997 to 2005. Dr. MacDonald held a Manitoba Cancer Treatment Research Foundation Fellowship from 1996 to 1997 while serving as a post-doctoral fellow at the University of Manitoba Cancer Treatment Research Foundation from 1995 to 1997. Dr. MacDonald also served as a Canadian Arthritis Society post-doctoral fellow at the University of North Carolina at Chapel Hill from 1993 to 1995. He graduated from the University of Guelph with a bachelor’s degree in genetics in 1980 and earned an M.Sc. and Ph.D. from the University of Manitoba in 1987 and 1993 respectively. Dr. MacDonald’s scientific background is extensive, having published in the areas of monoclonal antibodies, graft versus-host disease, lupus and apoptosis.- Glen MacDonald自2017年2月起担任我们的首席技术官。从2016年9月我们收购Viventia BioInc.到2017年2月，麦克唐纳博士担任我们的首席科学官。麦克唐纳博士于2012年至2016年9月担任Viventia BioInc.的首席科学官，并于2005年至2012年担任Viventia BioInc.的前身公司Viventia Biotech Inc.的首席科学官。在此之前，MacDonald从1997年到2005年担任Viventia Biotech Inc.多个研究相关职位。MacDonald博士从1996年到1997年持有马尼托巴癌症治疗研究基金会奖学金，同时从1995年到1997年担任马尼托巴大学癌症治疗研究基金会博士后。MacDonald博士还从1993年到1995年担任the University of North Carolina at Chapel Hill加拿大关节炎学会博士后研究员。他于1980年毕业于盖尔夫大学，获得遗传学学士学位，并获得理学硕士学位。以及1987年和1993年获得the University of Manitoba博士学位。
- Glen MacDonald has served as our Chief Technology Officer since February 2017. From the time of our acquisition of Viventia Bio Inc. in September 2016 to February 2017 Dr. MacDonald served as our Chief Scientific Officer. Dr. MacDonald was Chief Scientific Officer of Viventia Bio Inc. from 2012 to September 2016 and of Viventia Bio Inc.'s predecessor company, Viventia Biotech Inc., from 2005 to 2012. Prior to that, Dr. MacDonald served Viventia Biotech Inc. in several research related capacities from 1997 to 2005. Dr. MacDonald held a Manitoba Cancer Treatment Research Foundation Fellowship from 1996 to 1997 while serving as a post-doctoral fellow at the University of Manitoba Cancer Treatment Research Foundation from 1995 to 1997. Dr. MacDonald also served as a Canadian Arthritis Society post-doctoral fellow at the University of North Carolina at Chapel Hill from 1993 to 1995. He graduated from the University of Guelph with a bachelor’s degree in genetics in 1980 and earned an M.Sc. and Ph.D. from the University of Manitoba in 1987 and 1993 respectively. Dr. MacDonald’s scientific background is extensive, having published in the areas of monoclonal antibodies, graft versus-host disease, lupus and apoptosis.
- Mark R. Sullivan
MarkR.Sullivan自2019年8月起担任我们的总法律顾问兼公司秘书。从2018年4月至2019年8月，他担任我们的代理总法律顾问。2012年8月至2018年3月，他担任生命科学公司的私人顾问。此前，他曾担任MModalInc.的总法律顾问、首席合规官和秘书。纳斯达克市场代码:MODL，前身为领先的梦百合IT公司Medquist，Inc.，从2006年9月到2012年7月，MModal被摩根大通公司（JP Morgan Chase&Co.）的私人投资部门One Equity Partners收购。从2004年8月到2006年9月，Sullivan先生担任MModal MQ Inc.的代理总法律顾问。Sullivan从2003年3月到2004年8月担任MModal MQ Inc.副总法律顾问和助理秘书。加入MModal之前，Sullivan从2000年到2003年在Pepper Hamilton LLP和Drinker Biddle&Reath LLP从事私人执业。Sullivan先生在宾夕法尼亚大学（University of Pennsylvania）获得学士学位，在罗格斯大学法学院（Rutgers University School of Law）获得法学博士学位。
Mark R. Sullivan has served as our General Counsel and Corporate Secretary since August 2019. From April 2018 to August 2019 he served as our Acting General Counsel. From August 2012 through March 2018 he served as a private consultant to life sciences companies. Previously, he served as the General Counsel, Chief Compliance Officer and Secretary of MModal Inc. Nasdaq: MODL, formerly MedQuist, Inc., a leading healthcare IT company, from September 2006 until July 2012 when MModal was taken private by One Equity Partners, the private investment arm of JP Morgan Chase & Co. From August 2004 until September 2006 Mr. Sullivan was the Acting General Counsel of MModal MQ Inc. Between March 2003 and August 2004 Mr. Sullivan served as Associate General Counsel and Assistant Secretary of MModal MQ Inc. Prior to joining MModal, Mr. Sullivan was in private practice with Pepper Hamilton LLP from 2000 to 2003 and Drinker Biddle & Reath LLP from 1998 to 2000. Mr. Sullivan received a B.A. from the University of Pennsylvania and a J.D. from the Rutgers University School of Law.- MarkR.Sullivan自2019年8月起担任我们的总法律顾问兼公司秘书。从2018年4月至2019年8月，他担任我们的代理总法律顾问。2012年8月至2018年3月，他担任生命科学公司的私人顾问。此前，他曾担任MModalInc.的总法律顾问、首席合规官和秘书。纳斯达克市场代码:MODL，前身为领先的梦百合IT公司Medquist，Inc.，从2006年9月到2012年7月，MModal被摩根大通公司（JP Morgan Chase&Co.）的私人投资部门One Equity Partners收购。从2004年8月到2006年9月，Sullivan先生担任MModal MQ Inc.的代理总法律顾问。Sullivan从2003年3月到2004年8月担任MModal MQ Inc.副总法律顾问和助理秘书。加入MModal之前，Sullivan从2000年到2003年在Pepper Hamilton LLP和Drinker Biddle&Reath LLP从事私人执业。Sullivan先生在宾夕法尼亚大学（University of Pennsylvania）获得学士学位，在罗格斯大学法学院（Rutgers University School of Law）获得法学博士学位。
- Mark R. Sullivan has served as our General Counsel and Corporate Secretary since August 2019. From April 2018 to August 2019 he served as our Acting General Counsel. From August 2012 through March 2018 he served as a private consultant to life sciences companies. Previously, he served as the General Counsel, Chief Compliance Officer and Secretary of MModal Inc. Nasdaq: MODL, formerly MedQuist, Inc., a leading healthcare IT company, from September 2006 until July 2012 when MModal was taken private by One Equity Partners, the private investment arm of JP Morgan Chase & Co. From August 2004 until September 2006 Mr. Sullivan was the Acting General Counsel of MModal MQ Inc. Between March 2003 and August 2004 Mr. Sullivan served as Associate General Counsel and Assistant Secretary of MModal MQ Inc. Prior to joining MModal, Mr. Sullivan was in private practice with Pepper Hamilton LLP from 2000 to 2003 and Drinker Biddle & Reath LLP from 1998 to 2000. Mr. Sullivan received a B.A. from the University of Pennsylvania and a J.D. from the Rutgers University School of Law.